Literature DB >> 23307451

Fulminant hepatitis following chemotherapy treatment for breast cancer.

Ali Hakim Shoushtari1, Robert A Shaw.   

Abstract

A woman in her early 50s was admitted to the intensive care unit with nausea, altered mental status and hepatic failure. She had a history of asymptomatic chronic hepatitis B and recently received chemotherapy for breast cancer. A diagnosis of hepatitis B reactivation (HBR) was made, but unfortunately she died of liver failure. Controversies around testing for hepatitis B prior to giving immunosuppressive treatments and the use of prophylactic antiviral therapy to prevent HBR are discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23307451      PMCID: PMC3604245          DOI: 10.1136/bcr-2012-007017

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  20 in total

Review 1.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

Authors:  Winnie Yeo; Philip J Johnson
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 2.  Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management.

Authors:  L Xunrong; A W Yan; R Liang; G K Lau
Journal:  Rev Med Virol       Date:  2001 Sep-Oct       Impact factor: 6.989

3.  Prevalence of markers of hepatitis B in the adult German population.

Authors:  W Jilg; B Hottenträger; K Weinberger; K Schlottmann; E Frick; A Holstege; J Schölmerich; K D Palitzsch
Journal:  J Med Virol       Date:  2001-02       Impact factor: 2.327

4.  Hepatitis B virus infection in Chinese families in Hong Kong.

Authors:  A S Lok; C L Lai; P C Wu; V C Wong; E K Yeoh; H J Lin
Journal:  Am J Epidemiol       Date:  1987-09       Impact factor: 4.897

5.  Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.

Authors:  R M Galbraith; A L Eddleston; R Williams; A J Zuckerman
Journal:  Lancet       Date:  1975-09-20       Impact factor: 79.321

6.  Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.

Authors:  Cindy M Weinbaum; Eric E Mast; John W Ward
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

7.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

8.  A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ming-Yang Lai; Jia-Horng Kao; Ching-Fung Chang; Hui-Lin Wu; Wen-Yi Shau; Ding-Shinn Chen
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

9.  American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.

Authors:  Andrew S Artz; Mark R Somerfield; Jordan J Feld; Andrew F Giusti; Barnett S Kramer; Anita L Sabichi; Robin T Zon; Sandra L Wong
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.